Phio Pharmaceuticals (PHIO)
(Real Time Quote from BATS)
$2.29 USD
-0.06 (-2.55%)
Updated Aug 6, 2025 02:28 PM ET
3-Hold of 5 3
C Value C Growth C Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PHIO 2.29 -0.06(-2.55%)
Will PHIO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PHIO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PHIO
Best Value Stocks to Buy for May 28th
New Strong Buy Stocks for May 28th
PHIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Best Momentum Stocks to Buy for April 23rd
Best Value Stocks to Buy for April 23rd
PHIO Stock Soars as Safety Panel Clears Skin Cancer Drug for Next Dose
Other News for PHIO
12 Health Care Stocks Moving In Friday's Intraday Session
Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort | ...
Phio Pharmaceuticals (PHIO) Shares Surge on New Manufacturing Agreement
Phio Pharmaceuticals stock jumps 24% on partnering with U.S. drug substance manufacturer
12 Health Care Stocks Moving In Friday's Pre-Market Session